Convatec boosts outlook after strong year, shares spark

(Sharecast News) - Shares in Convatec Group sparked in early trading on Monday, after the medical products business boosted medium-term guidance following a jump in annual sales and earnings. The blue chip, which specialises in advanced wound management alongside ostomy, continence and infusion care, saw adjusted revenues rise 5% to $2.4bn on a constant currency basis in the year to December end. Operating profits were 10.2% stronger on the same basis at $544m.

Convatec said it had seen organic growth across all categories, boosted by new product launches and improvements in the operating margin.

Jonny Mason, chief executive, called it a strong performance.

"Convatec performed strongly in 2025, demonstrating further resilient growth," he said. "Looking ahead, we are increasing our medium-term revenue growth target to 6% to 8% from 2027. This acceleration follows the successful implementation of our strategy and is underpinned by our rich innovation pipeline."

Convatec had previously forecast medium-term organic revenue growth of between 5% and 7%.

As at 0830 GMT, the stock was up 9% at 247p.

Looking to the current year, the firm said revenue growth would likely be weighed to the second half, but reiterated guidance for double digit adjusted EPS growth.